{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:03:05Z","timestamp":1795024985601,"version":"4.10.2"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40266-025-01195-4","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:23:26Z","timestamp":1744176206000},"page":"413-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of Late-Onset Rheumatoid Arthritis with Treat-to-Target Strategy"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7494","authenticated-orcid":false,"given":"Takahiko","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"10416","key":"1195_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019\u201333.","journal-title":"Lancet"},{"issue":"1","key":"1195_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Tanaka E, Nakajima A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options. Mod Rheumatol. 2020;30(1):1\u20136.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1195_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-023-03251-z","volume":"26","author":"T Fujii","year":"2024","unstructured":"Fujii T, Murata K, Onizawa H, et al. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. Arthritis Res Ther. 2024;26(1):16.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1195_CR4","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/rheumatology\/kead539","volume":"63","author":"H Yamada","year":"2024","unstructured":"Yamada H, Jinno S, Maeda T, et al. Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021: the ANSWER cohort study. Rheumatology (Oxford). 2024;63(8):2147\u201351.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1195_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1195_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1195_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/mr\/roae049","volume":"34","author":"Y Nakayama","year":"2024","unstructured":"Nakayama Y, Nagata W, Takeuchi Y, et al. Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2024;34(6):1079\u201394.","journal-title":"Mod Rheumatol"},{"key":"1195_CR8","doi-asserted-by":"crossref","unstructured":"He J, Wang Y, Liu Q, Li R. Theory and practice of treat-to-target (T2T) in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2025;39(1):102018.","DOI":"10.1016\/j.berh.2024.102018"},{"issue":"2","key":"1195_CR9","doi-asserted-by":"publisher","first-page":"e003196","DOI":"10.1136\/rmdopen-2023-003196","volume":"9","author":"MA Messelink","year":"2023","unstructured":"Messelink MA, den Broeder AA, Marinelli FE, et al. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 2023;9(2):e003196. https:\/\/doi.org\/10.1136\/rmdopen-2023-003196.","journal-title":"RMD Open"},{"key":"1195_CR10","doi-asserted-by":"crossref","unstructured":"Sugano E, Tanaka E, Inoue E, et al. Differences in patients\u2019 population and efficacy\/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis\u2014using the IORRA cohort. Mod Rheumatol. 2022;32(4):675\u201385.","DOI":"10.1093\/mr\/roab067"},{"key":"1195_CR11","unstructured":"Cabinet_Office. 2024 annual report on the ageing society. In: Annual report on the ageing society. 2024. https:\/\/www8.cao.go.jp\/kourei\/whitepaper\/w-2024\/zenbun\/06pdf_index.html. Accessed 11 Feb 2025."},{"issue":"10033","key":"1195_CR12","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/S0140-6736(15)00516-4","volume":"387","author":"JR Beard","year":"2016","unstructured":"Beard JR, Officer A, de Carvalho IA, et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet. 2016;387(10033):2145\u201354.","journal-title":"Lancet"},{"issue":"2","key":"1195_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40266-015-0341-2","volume":"33","author":"T Sugihara","year":"2016","unstructured":"Sugihara T, Harigai M. Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs. Drugs Aging. 2016;33(2):97\u2013107.","journal-title":"Drugs Aging"},{"issue":"10","key":"1195_CR14","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3390\/medicina59101878","volume":"59","author":"S Pavlov-Dolijanovic","year":"2023","unstructured":"Pavlov-Dolijanovic S, Bogojevic M, Nozica-Radulovic T, Radunovic G, Mujovic N. Elderly-onset rheumatoid arthritis: characteristics and treatment options. Medicina (Kaunas). 2023;59(10):1878. https:\/\/doi.org\/10.3390\/medicina59101878.","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"1195_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: characteristics and treatment considerations. Autoimmun Rev. 2020;19(6): 102528.","journal-title":"Autoimmun Rev"},{"key":"1195_CR16","doi-asserted-by":"crossref","unstructured":"Matsui T, Yoshida T, Nishino T, Yoshizawa S, Sawada T, Tohma S. Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: data from the NinJa study. Mod Rheumatol. 2024;34(5):881\u201391.","DOI":"10.1093\/mr\/roae006"},{"issue":"5","key":"1195_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/rheumatology\/keu395","volume":"54","author":"T Sugihara","year":"2015","unstructured":"Sugihara T, Ishizaki T, Hosoya T, et al. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). Rheumatology (Oxford). 2015;54(5):798\u2013807.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1195_CR18","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1093\/rheumatology\/keaa922","volume":"60","author":"T Sugihara","year":"2021","unstructured":"Sugihara T, Ishizaki T, Onoguchi W, et al. Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study. Rheumatology (Oxford). 2021;60(9):4252\u201361.","journal-title":"Rheumatology (Oxford)"},{"key":"1195_CR19","doi-asserted-by":"crossref","unstructured":"Jinno S, Onishi A, Hattori S, et al. Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis\u2014the ANSWER cohort study. Rheumatology (Oxford). 2025;64(2):509\u201316.","DOI":"10.1093\/rheumatology\/keae081"},{"issue":"12","key":"1195_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/acr2.11625","volume":"5","author":"J Lee","year":"2023","unstructured":"Lee J, Martindale J, Makris UE, Singh N, Yung R, Bynum JPW. Initiation of disease-modifying antirheumatic drugs in older medicare beneficiaries with new diagnosis of late-onset rheumatoid arthritis. ACR Open Rheumatol. 2023;5(12):694\u2013700.","journal-title":"ACR Open Rheumatol."},{"key":"1195_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/OARRR.S306378","volume":"13","author":"J Nilsson","year":"2021","unstructured":"Nilsson J, Andersson MLE, Hafstrom I, et al. Influence of age and sex on disease course and treatment in rheumatoid arthritis. Open Access Rheumatol. 2021;13:123\u201338.","journal-title":"Open Access Rheumatol"},{"issue":"4","key":"1195_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/ard.2009.123976","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis. 2010;69(4):638\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1195_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","volume":"75","author":"MA Stoffer","year":"2016","unstructured":"Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75(1):16\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1195_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1195_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1195_CR26","doi-asserted-by":"publisher","unstructured":"Harigai M, Kaneko Y, Tanaka E, et al. 2024 Update of Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis\u2014secondary publication. Mod Rheumatol. 2025;roaf006. https:\/\/doi.org\/10.1093\/mr\/roaf006. Epub ahead of print.","DOI":"10.1093\/mr\/roaf006"},{"issue":"9","key":"1195_CR27","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"1195_CR28","doi-asserted-by":"crossref","unstructured":"Takanashi S, Kaneko Y, Kawahito Y, et al. A preliminary survey of rheumatologists on the management of late-onset rheumatoid arthritis in Japan. Intern Med. 2024;63(24):3299\u2013306.","DOI":"10.2169\/internalmedicine.3288-23"},{"issue":"7","key":"1195_CR29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/ggi.13118","volume":"17","author":"Y Ouchi","year":"2017","unstructured":"Ouchi Y, Rakugi H, Arai H, et al. Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol Int. 2017;17(7):1045\u20137.","journal-title":"Geriatr Gerontol Int"},{"issue":"3","key":"1195_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/mr\/roab087","volume":"32","author":"T Sugihara","year":"2022","unstructured":"Sugihara T. Treatment strategies for elderly-onset rheumatoid arthritis in the new era. Mod Rheumatol. 2022;32(3):493\u20139.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"1195_CR31","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.semarthrit.2020.03.018","volume":"50","author":"VC Romao","year":"2020","unstructured":"Romao VC, Humby F, Kelly S, et al. Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study. Semin Arthritis Rheum. 2020;50(4):735\u201343.","journal-title":"Semin Arthritis Rheum"},{"key":"1195_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152635","volume":"71","author":"M Shimizu","year":"2025","unstructured":"Shimizu M, Paudel ML, Shadick N, Weinblatt M, Solomon DH. Age of onset of rheumatoid arthritis and radiographic changes. Semin Arthritis Rheum. 2025;71: 152635.","journal-title":"Semin Arthritis Rheum"},{"key":"1195_CR33","doi-asserted-by":"publisher","unstructured":"Sugitani N, Tanaka E, Inoue E, et al. Higher risk of poor functional outcome and unfavorable clinical events for late-onset rheumatoid arthritis: results from the IORRA cohort. Rheumatology (Oxford). 2024;keae673. https:\/\/doi.org\/10.1093\/rheumatology\/keae673. Epub ahead of print.","DOI":"10.1093\/rheumatology\/keae673"},{"issue":"2","key":"1195_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/mr\/roab013","volume":"32","author":"S Uchiyama","year":"2022","unstructured":"Uchiyama S, Takanashi S, Takeno M, et al. Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society? Mod Rheumatol. 2022;32(2):323\u20139.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1195_CR35","doi-asserted-by":"publisher","first-page":"rkae019","DOI":"10.1093\/rap\/rkae019","volume":"8","author":"T Matsumoto","year":"2024","unstructured":"Matsumoto T, Sugihara T, Hosoya T, et al. Effectiveness and safety of treat-to-target strategy for methotrexate-naive rheumatoid arthritis patients > 75 years of age. Rheumatol Adv Pract. 2024;8(1):rkae019.","journal-title":"Rheumatol Adv Pract."},{"issue":"1","key":"1195_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13075-022-02952-1","volume":"24","author":"X Li","year":"2022","unstructured":"Li X, Cesta A, Movahedi M, Bombardier C. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative. Arthritis Res Ther. 2022;24(1):255.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1195_CR37","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/mr\/roae011","volume":"34","author":"M Kojima","year":"2024","unstructured":"Kojima M, Sugihara T, Kawahito Y, et al. Consensus statement on the management of late-onset rheumatoid arthritis. Mod Rheumatol. 2024;34(6):1095\u2013102.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"1195_CR38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra2301292","volume":"391","author":"DH Kim","year":"2024","unstructured":"Kim DH, Rockwood K. Frailty in older adults. N Engl J Med. 2024;391(6):538\u201348.","journal-title":"N Engl J Med"},{"issue":"11","key":"1195_CR39","doi-asserted-by":"publisher","first-page":"1002 e7","DOI":"10.1016\/j.jamda.2015.08.001","volume":"16","author":"M Yamada","year":"2015","unstructured":"Yamada M, Arai H. Predictive value of frailty scores for healthy life expectancy in community-dwelling older Japanese adults. J Am Med Dir Assoc. 2015;16(11):1002 e7-1002 e11.","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"1195_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.14283\/jfa.2020.1","volume":"9","author":"I Yoshii","year":"2020","unstructured":"Yoshii I, Kondo M. Clinical characteristics of frailty in Japanese rheumatoid arthritis patients. J Frailty Aging. 2020;9(3):158\u201364.","journal-title":"J Frailty Aging"},{"key":"1195_CR41","doi-asserted-by":"crossref","unstructured":"Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis. 2012;71(12):1921\u20133.","DOI":"10.1136\/annrheumdis-2012-201893"},{"issue":"4","key":"1195_CR42","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1016\/S2666-7568(24)00007-2","volume":"5","author":"K Nicholson","year":"2024","unstructured":"Nicholson K, Liu W, Fitzpatrick D, et al. Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review. Lancet Healthy Longev. 2024;5(4):e287\u201396.","journal-title":"Lancet Healthy Longev."},{"issue":"6","key":"1195_CR43","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1756-185X.13428","volume":"22","author":"K Murata","year":"2019","unstructured":"Murata K, Ito H, Hashimoto M, et al. Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int J Rheum Dis. 2019;22(6):1084\u201393.","journal-title":"Int J Rheum Dis"},{"key":"1195_CR44","doi-asserted-by":"crossref","unstructured":"Asai S, Suzuki M, Hara R, et al. Comparison of effectiveness of methotrexate in patients with late-onset versus younger-onset rheumatoid arthritis: real-world data from an inception cohort in Japan (NICER-J). Mod Rheumatol. 2024;34(5):892\u20139.","DOI":"10.1093\/mr\/roae027"},{"issue":"1","key":"1195_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mr\/road098","volume":"34","author":"H Kameda","year":"2023","unstructured":"Kameda H, Yamaoka K, Yamanishi Y, et al. Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication. Mod Rheumatol. 2023;34(1):1\u201310.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"1195_CR46","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/1756-185X.13974","volume":"23","author":"A Nakajima","year":"2020","unstructured":"Nakajima A, Sakai R, Inoue E, Harigai M. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis. 2020;23(12):1676\u201384.","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"1195_CR47","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00296-020-04660-y","volume":"40","author":"S Jinno","year":"2020","unstructured":"Jinno S, Onishi A, Dubreuil M, et al. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatol Int. 2020;40(12):1987\u201395.","journal-title":"Rheumatol Int"},{"issue":"8","key":"1195_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40266-024-01133-w","volume":"41","author":"T Sugihara","year":"2024","unstructured":"Sugihara T, Tanaka E, Matsui T. Low-dose glucocorticoids in older patients with rheumatoid arthritis: what does the evidence say? Drugs Aging. 2024;41(8):641\u201352.","journal-title":"Drugs Aging"},{"issue":"2","key":"1195_CR49","first-page":"234","volume":"33","author":"JM Bathon","year":"2006","unstructured":"Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33(2):234\u201343.","journal-title":"J Rheumatol"},{"issue":"12","key":"1195_CR50","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","volume":"48","author":"MD Koller","year":"2009","unstructured":"Koller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford). 2009;48(12):1575\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"1195_CR51","doi-asserted-by":"crossref","unstructured":"Sugihara T, Kawahito Y, Kaneko Y, et al. Systematic review for the treatment of older rheumatoid arthritis patients informing the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2024;34(5):867\u201380.","DOI":"10.1093\/mr\/roae026"},{"issue":"8","key":"1195_CR52","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3899\/jrheum.130901","volume":"41","author":"H Matsubara","year":"2014","unstructured":"Matsubara H, Kojima T, Kaneko A, et al. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy. J Rheumatol. 2014;41(8):1583\u20139.","journal-title":"J Rheumatol"},{"issue":"5","key":"1195_CR53","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/acr.22510","volume":"67","author":"J Zhang","year":"2015","unstructured":"Zhang J, Xie F, Delzell E, et al. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2015;67(5):624\u201332.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"9","key":"1195_CR54","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/rheumatology\/kez671","volume":"59","author":"K Bechman","year":"2020","unstructured":"Bechman K, Oke A, Yates M, et al. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2020;59(9):2563\u201371.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1195_CR55","first-page":"1657","volume":"40","author":"C Specker","year":"2022","unstructured":"Specker C, Aringer M, Burmester GR, et al. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clin Exp Rheumatol. 2022;40(9):1657\u201365.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1195_CR56","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","volume":"55","author":"C Lahaye","year":"2016","unstructured":"Lahaye C, Soubrier M, Mulliez A, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology\u2019s ORA registry. Rheumatology (Oxford). 2016;55(5):874\u201382.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1195_CR57","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3899\/jrheum.160051","volume":"43","author":"M Sekiguchi","year":"2016","unstructured":"Sekiguchi M, Fujii T, Matsui K, et al. Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD study. J Rheumatol. 2016;43(11):1974\u201383.","journal-title":"J Rheumatol"},{"issue":"4","key":"1195_CR58","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s40744-021-00356-2","volume":"8","author":"S Muraoka","year":"2021","unstructured":"Muraoka S, Yamada Z, Kawazoe M, et al. Abatacept is efficacious in the treatment of older patients with csDMARD-refractory rheumatoid arthritis: a prospective, multicenter, observational study. Rheumatol Ther. 2021;8(4):1585\u2013601.","journal-title":"Rheumatol Ther."},{"issue":"4","key":"1195_CR59","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","volume":"26","author":"M Harigai","year":"2016","unstructured":"Harigai M, Ishiguro N, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26(4):491\u20138.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"1195_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000546","volume":"3","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Alam J, Arora V, et al. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open. 2017;3(2): e000546.","journal-title":"RMD Open"},{"issue":"3","key":"1195_CR61","first-page":"390","volume":"35","author":"JR Curtis","year":"2017","unstructured":"Curtis JR, Schulze-Koops H, Takiya L, et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(3):390\u2013400.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1195_CR62","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/mr\/roab058","volume":"32","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Miyatake D. Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis. Mod Rheumatol. 2022;32(4):696\u2013707.","journal-title":"Mod Rheumatol"},{"issue":"16","key":"1195_CR63","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383(16):1511\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1195_CR64","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/annrheumdis-2016-209212","volume":"76","author":"P Verschueren","year":"2017","unstructured":"Verschueren P, De Cock D, Corluy L, et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis. 2017;76(3):511\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1195_CR65","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","volume":"156","author":"MF Bakker","year":"2012","unstructured":"Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329\u201339.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1195_CR66","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/annrheumdis-2013-205143","volume":"74","author":"MM ter Wee","year":"2015","unstructured":"ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis. 2015;74(6):1233\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1195_CR67","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1136\/annrheumdis-2013-203497","volume":"73","author":"V Rantalaiho","year":"2014","unstructured":"Rantalaiho V, Kautiainen H, Korpela M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis. 2014;73(11):1954\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1195_CR68","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/ard.2010.141234","volume":"70","author":"NB Klarenbeek","year":"2011","unstructured":"Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70(6):1039\u201346.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1195_CR69","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/annrheumdis-2013-203243","volume":"73","author":"L Heimans","year":"2014","unstructured":"Heimans L, Wevers-de Boer KV, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis. 2014;73(7):1356\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1195_CR70","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/ard-2022-223358","volume":"82","author":"SA Bergstra","year":"2023","unstructured":"Bergstra SA, Sepriano A, Kerschbaumer A, et al. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):81\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1195_CR71","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/annrheumdis-2016-210711","volume":"76","author":"K Chatzidionysiou","year":"2017","unstructured":"Chatzidionysiou K, Emamikia S, Nam J, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1102\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1195_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152219","volume":"61","author":"LP Crowson","year":"2023","unstructured":"Crowson LP, Davis JM 3rd, Hanson AC, et al. Time trends in glucocorticoid use in rheumatoid arthritis during the biologics era: 1999\u20132018. Semin Arthritis Rheum. 2023;61: 152219.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1195_CR73","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","volume":"81","author":"M Boers","year":"2022","unstructured":"Boers M, Hartman L, Opris-Belinski D, et al. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022;81(7):925\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1195_CR74","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/ard-2023-223977","volume":"82","author":"AAH Almayali","year":"2023","unstructured":"Almayali AAH, Boers M, Hartman L, et al. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. Ann Rheum Dis. 2023;82(10):1307\u201314.","journal-title":"Ann Rheum Dis"},{"key":"1195_CR75","first-page":"460","volume":"74","author":"N Sugitani","year":"2022","unstructured":"Sugitani N, Tanaka E, Inoue E, et al. Real world evidence of treatment effectiveness and unfavorable clinical events for elderly-onset early rheumatoid arthritis in Japan: results from the IORRA study. Arthritis Rheumatol. 2022;74:460\u20132.","journal-title":"Arthritis Rheumatol"},{"key":"1195_CR76","doi-asserted-by":"crossref","unstructured":"Tamai H, Ikeda K, Miyamoto T, et al. Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial. Ann Rheum Dis. 2025;84(1):41\u20138.","DOI":"10.1136\/ard-2024-226350"},{"issue":"3","key":"1195_CR77","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/14397595.2015.1088620","volume":"26","author":"K Saisho","year":"2016","unstructured":"Saisho K, Yoshikawa N, Sugata K, Hamada H, Tohma S. Prevalence of chronic kidney disease and administration of RA-related drugs in patients with RA: the NinJa 2012 study in Japan. Mod Rheumatol. 2016;26(3):331\u20135.","journal-title":"Mod Rheumatol"},{"issue":"9","key":"1195_CR78","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/ard.2005.051144","volume":"65","author":"Z Tutuncu","year":"2006","unstructured":"Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65(9):1226\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1195_CR79","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3899\/jrheum.140533","volume":"42","author":"A Hashimoto","year":"2015","unstructured":"Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42(4):564\u201371.","journal-title":"J Rheumatol"},{"issue":"1","key":"1195_CR80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/14397595.2021.1899570","volume":"32","author":"H Takada","year":"2022","unstructured":"Takada H, Kaneko Y, Nakano K, et al. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: a retrospective, multicenter, descriptive study. Mod Rheumatol. 2022;32(1):32\u201340.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1195_CR81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/14397595.2020.1869370","volume":"32","author":"S Honda","year":"2022","unstructured":"Honda S, Sakai R, Inoue E, et al. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study. Mod Rheumatol. 2022;32(1):16\u201323.","journal-title":"Mod Rheumatol"},{"key":"1195_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152301","volume":"63","author":"M Mizushima","year":"2023","unstructured":"Mizushima M, Sugihara T, Matsui T, Urata Y, Tohma S, Kawahata K. Comparison between rheumatoid arthritis with malignant lymphoma and other malignancies: analysis of a National Database of Rheumatic Disease in Japan. Semin Arthritis Rheum. 2023;63: 152301.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1195_CR83","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40266-019-00691-8","volume":"36","author":"CJ Edwards","year":"2019","unstructured":"Edwards CJ, Roshak K, Bukowski JF, et al. Efficacy and safety of etanercept in elderly patients with rheumatoid arthritis: a post-hoc analysis of randomized controlled trials. Drugs Aging. 2019;36(9):853\u201362.","journal-title":"Drugs Aging"},{"issue":"1","key":"1195_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40266-019-00721-5","volume":"37","author":"CJ Edwards","year":"2020","unstructured":"Edwards CJ, Bukowski JF, Burns SM, et al. An analysis of real-world data on the safety of etanercept in older patients with rheumatoid arthritis. Drugs Aging. 2020;37(1):35\u201341.","journal-title":"Drugs Aging"},{"issue":"11","key":"1195_CR85","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.3899\/jrheum.160012","volume":"43","author":"A Murota","year":"2016","unstructured":"Murota A, Kaneko Y, Yamaoka K, Takeuchi T. Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatol. 2016;43(11):1984\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"1195_CR86","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-022-02807-9","volume":"24","author":"R Sakai","year":"2022","unstructured":"Sakai R, Tanaka E, Majima M, Harigai M. Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study. Arthritis Res Ther. 2022;24(1):135.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1195_CR87","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1195_CR88","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14397595.2021.1912922","volume":"32","author":"T Sugihara","year":"2022","unstructured":"Sugihara T, Kawahito Y, Morinobu A, et al. Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2022;32(2):313\u201322.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1195_CR89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13075-024-03323-8","volume":"26","author":"Z Yamada","year":"2024","unstructured":"Yamada Z, Muraoka S, Kawazoe M, et al. Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study. Arthritis Res Ther. 2024;26(1):87.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1195_CR90","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/acr.23426","volume":"70","author":"NA Accortt","year":"2018","unstructured":"Accortt NA, Lesperance T, Liu M, et al. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018;70(5):679\u201384.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"10","key":"1195_CR91","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/annrheumdis-2016-210997","volume":"76","author":"EE Arts","year":"2017","unstructured":"Arts EE, Fransen J, Den Broeder AA, van Riel P, Popa CD. Low disease activity (DAS28 \u2264 3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017;76(10):1693\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1195_CR92","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2018-214075","volume":"78","author":"B Burggraaf","year":"2019","unstructured":"Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2019;78(3):335\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1195_CR93","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1093\/rheumatology\/keac208","volume":"61","author":"R Brooks","year":"2022","unstructured":"Brooks R, Baker JF, Yang Y, et al. The impact of disease severity measures on survival in US veterans with rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). 2022;61(12):4667\u201377.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1195_CR94","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.40904","volume":"71","author":"JA Sparks","year":"2019","unstructured":"Sparks JA, He X, Huang J, et al. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol. 2019;71(9):1472\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1195_CR95","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/annrheumdis-2020-218992","volume":"80","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Citera G, Gold D, et al. Age-based (< 65 vs \u2265 65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Ann Rheum Dis. 2021;80(1):134\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1195_CR96","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/art.40911","volume":"71","author":"C Charles-Schoeman","year":"2019","unstructured":"Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1450\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1195_CR97","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/ard-2022-222543","volume":"82","author":"JR Curtis","year":"2023","unstructured":"Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1195_CR98","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81(6):798\u2013804.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1195_CR99","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/art.42250","volume":"74","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC. Tofacitinib and risk of malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. Arthritis Rheumatol. 2022;74(10):1648\u201359.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1195_CR100","first-page":"201","volume":"10","author":"CA Salinas","year":"2023","unstructured":"Salinas CA, Louder A, Polinski J, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther. 2023;10(1):201\u201323.","journal-title":"Rheumatol Ther."},{"issue":"7","key":"1195_CR101","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/ard-2022-223636","volume":"82","author":"V Huss","year":"2023","unstructured":"Huss V, Bower H, Hellgren K, et al. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023;82(7):911\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1195_CR102","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/kead163","volume":"63","author":"R Westermann","year":"2024","unstructured":"Westermann R, Cordtz RL, Duch K, et al. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study. Rheumatology (Oxford). 2024;63(1):93\u2013102.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1195_CR103","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/ard-2022-222824","volume":"82","author":"L Hoisnard","year":"2023","unstructured":"Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2023;82(2):182\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1195_CR104","doi-asserted-by":"publisher","first-page":"e003489","DOI":"10.1136\/rmdopen-2023-003489","volume":"9","author":"Y Meissner","year":"2023","unstructured":"Meissner Y, Schafer M, Albrecht K, et al. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open. 2023;9(4):e003489. https:\/\/doi.org\/10.1136\/rmdopen-2023-003489.","journal-title":"RMD Open"},{"issue":"2","key":"1195_CR105","doi-asserted-by":"publisher","first-page":"e003885","DOI":"10.1136\/rmdopen-2023-003885","volume":"10","author":"R Sakai","year":"2024","unstructured":"Sakai R, Tanaka E, Inoue E, Harigai M. Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database. RMD Open. 2024;10(2):e003885. https:\/\/doi.org\/10.1136\/rmdopen-2023-003885.","journal-title":"RMD Open"},{"issue":"12","key":"1195_CR106","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1136\/ard.2011.151092","volume":"70","author":"T Koike","year":"2011","unstructured":"Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70(12):2148\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1195_CR107","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3899\/jrheum.141210","volume":"42","author":"K Yamamoto","year":"2015","unstructured":"Yamamoto K, Goto H, Hirao K, et al. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol. 2015;42(8):1368\u201375.","journal-title":"J Rheumatol"},{"issue":"5","key":"1195_CR108","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/14397595.2018.1524998","volume":"29","author":"M Harigai","year":"2019","unstructured":"Harigai M, Ishiguro N, Inokuma S, et al. Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Mod Rheumatol. 2019;29(5):747\u201355.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"1195_CR109","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/M20-1594","volume":"173","author":"MD George","year":"2020","unstructured":"George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. Ann Intern Med. 2020;173(11):870\u20138.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1195_CR110","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","volume":"71","author":"WG Dixon","year":"2012","unstructured":"Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case\u2013control analysis. Ann Rheum Dis. 2012;71(7):1128\u201333.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1195_CR111","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/rheumatology\/keab548","volume":"61","author":"S Abtahi","year":"2022","unstructured":"Abtahi S, Driessen JHM, Burden AM, et al. Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink. Rheumatology (Oxford). 2022;61(4):1448\u201358.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1195_CR112","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3899\/jrheum.180427","volume":"46","author":"J Widdifield","year":"2019","unstructured":"Widdifield J, Abrahamowicz M, Paterson JM, et al. Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis. J Rheumatol. 2019;46(5):467\u201374.","journal-title":"J Rheumatol"},{"issue":"11","key":"1195_CR113","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/art.42928","volume":"76","author":"BW Coburn","year":"2024","unstructured":"Coburn BW, Baker JF, Hsu JY, et al. Association of cardiovascular outcomes with low-dose glucocorticoid prescription in patients with rheumatoid arthritis. Arthritis Rheumatol. 2024;76(11):1585\u201393.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1195_CR114","doi-asserted-by":"publisher","first-page":"e002600","DOI":"10.1136\/rmdopen-2022-002600","volume":"8","author":"R Dietzel","year":"2022","unstructured":"Dietzel R, Wiegmann S, Borucki D, et al. Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition. RMD Open. 2022;8(2):e002600. https:\/\/doi.org\/10.1136\/rmdopen-2022-002600","journal-title":"RMD Open"},{"issue":"6","key":"1195_CR115","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s10067-020-04929-4","volume":"39","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Tada M, Mandai K, Hidaka N, Inui K, Nakamura H. Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol. 2020;39(6):1757\u201364.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1195_CR116","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-019-1968-x","volume":"21","author":"J Tesser","year":"2019","unstructured":"Tesser J, Kafka S, DeHoratius RJ, Xu S, Hsia EC, Turkiewicz A. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those \u2265 65 years of age. Arthritis Res Ther. 2019;21(1):190.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1195_CR117","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-020-02231-x","volume":"22","author":"P Vela","year":"2020","unstructured":"Vela P, Sanchez-Piedra C, Perez-Garcia C, et al. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. Arthritis Res Ther. 2020;22(1):143.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1195_CR118","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01195-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T14:03:31Z","timestamp":1746453811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01195-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":118,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01195-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"18 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.H. has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Eisai Co., Ltd., Eli Lilly Japan K.K., Kaken Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., UCB Japan Co., Ltd. and Viatris Japan; has received speaker\u2019s fees from AbbVie Japan GK, Asahi Kasei Corp., Astra Zeneca K. K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd. and Teijin Pharma Ltd; and is a consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd. and Teijin Pharma. T.S. has received research grants from Asahi KASEI Co., Ltd., Daiichi Sankyo., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical. TS has received honoraria from AbbVie Japan Co., Ltd., Asahi KASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc. and Taisho Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"No funding was received for this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.H. conceived the manuscript. M.H. and T.S. drafted and reviewed the manuscript critically for important intellectual content and approved the final version to be published. M.H. and T.S. have agreed to be accountable for all scientific aspects of the manuscript, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}